What Happened?
New York, -based Kadmon Resigned Gregory Moss as Executive Vice President, General Counsel and Corporate Secretary
About the Company
Kadmon is a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. We are developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. We leverage our multi-disciplinary research and clinical development team members, who prior to joining Kadmon had brought more than 15 drugs to market, to identify and pursue a diverse portfolio of novel product candidates, both through in-licensing products and employing our small molecule and biologics platforms. We utilize our advanced understanding of the molecular mechanisms of disease to establish development paths for disease areas where significant unmet medical needs exist.
About the Person
Gregory Moss is Chief Corporate Strategy and Legal Officer; Corporate Secretary and Chief Compliance Officer at Evommune. Previously, Gregory held various senior legal leadership roles in the industry.
Info Source
News
Short Profile